The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

UCB’s continued commitment to leading research aimed at improving treatment outcomes for people living with neurological conditions.Data include the use of FINTEPLA®▼ (fenfluramine)1 in Dravet ...

About this study The purpose of this study is to assess the effect of zorevunersen to reduce the frequency of major motor seizures in patients with DS. Major motor seizures are defined as the ...

While Harmony Biosciences HRMY may not be a typical cannabis stock involved in cultivation, processing, or sales of marijuana ...

A late-stage study has shown promising results for the effectiveness of fenfluramine in people with an ultra-rare form of epilepsy - CDKL5 deficiency disorder (CDD).

UCB has shared promising results from a late-stage study of fenfluramine in patients with an ultra-rare form of epilepsy. The ...

The Stanley Brothers created Charlotte's Web, the CBD supplement that’s worked wonders on seizures. Now they are developing ...

UCB announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency DisorderPhase 3 study met primary and key secondary clinical endpoints, marking the third developmental and ...

UCB has announced that its phase 3 trial evaluating fenfluramine in CDKL5 deficiency disorder (CDD) achieved its primary and ...

A Surbiton couple is backing a UK-wide campaign to raise awareness of a rare form of epilepsy that affects their daughter. Jennifer and Tom Allen's nine-year-old daughter, Beth, has Dravet Syndrome.

UCB’s Fintepla has been approved to treat seizures associated with two epilepsy disorders and now has posted data that could ...